ALACHUA, Fla.--(BUSINESS WIRE)--RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic’s announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.
